Andrew joined IP Asset in October 2016 as a trainee patent attorney having completed his PhD at the Medical Research Council’s Toxicology Unit in Leicester with Professor Andrew Tobin’s group. Andrew’s field of expertise is in cellular signalling and toxicology, with an emphasis on G Protein-Coupled Receptor pharmacology. Over the 4 years of his PhD he explored how these receptors interact with each other, and how compounds produce toxic events through such proteins.
Prior to his postgraduate study he worked for the successful drug-development start-up Heptares Therapeutics in Welwyn Garden City as part of their pharmacology team. Andrew also graduated with a class prize for ‘Best Student’ from the University of Edinburgh with a First Class (with Honours) BSc in Pharmacology.
In his spare time he enjoys adventure travel, music festivals, and is an avid cyclist: Both pedal powered and motorised.